Stockreport

Athira Pharma Announces Topline Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton for Mild-to-Moderate Alzheimer's Disease [Yahoo! Finance]

Athira Pharma, Inc.  (ATHA) 
PDF In pre-specified subgroups of patients with moderate Alzheimer's disease or who are APOE4 carriers, fosgonimeton showed a numerically greater treatment effect All bio [Read more]